Dexcom, the global leader in real-time continuous glucose monitoring for people with diabetes, has launched Stelo, the first over-the-counter glucose biosensor in the U.S. It is available for purchase online without a prescription. 
 
“Dexcom has been at the forefront of glucose biosensing for 25 years. With the launch of Stelo, we’re defining a brand-new category and once again setting the gold standard for people to easily take control of their health,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Now, millions more have access to 24/7, easy-to-understand glucose insights that can inform their daily lifestyle choices and support behavior modification.”
 
Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose-sensing technology. It is specifically designed to provide personalized glucose insights sent directly to a smartphone, showing how food, exercise, and sleep can affect glucose without the use of fingersticks.
 
“Dexcom glucose biosensors are an essential and proven tool for diabetes management – driving strong clinical outcomes regardless of medication use and even potentially slowing the progression of diabetes,” said Thomas Grace, MD, head of clinical advocacy and outcomes at Dexcom. “In a world where GLP-1 use is becoming increasingly more common, glucose biosensors like Stelo can help make those medications more effective.”
 
Stelo does not require the use of fingersticks and can be worn for up to 15 days. It has the highest waterproof rating and connects to an easy-to-use app. Stelo is the only over-the-counter glucose biosensor for people with diabetes featuring spike detection, designed to identify meaningful glucose variability as it happens so users can make informed changes.
 
Studies have shown that using Dexcom glucose sensors like Stelo helps lower A1c for people with Type 2 diabetes and may help slow the progression of diabetes. 
 
Stelo is currently available for purchase in the U.S. online and is FSA and HSA eligible. It is now part of Dexcom’s overall portfolio of glucose biosensors.